Jasper Therapeutics shares rise 10.91% intraday on positive ETESIAN study data and investor webinar announcement.

Jasper Therapeutics (JSPR) rose 10.91% intraday following the announcement of positive preliminary data from its ETESIAN study of Briquilimab in asthma and findings from the BEACON study investigation, both reported by GlobeNewswire two days prior. The company also disclosed plans to host an investor webinar on December 2nd to present these results, heightening market optimism. Recent clinical progress in asthma and internal investigations, coupled with investor engagement initiatives, likely drove the intraday surge. Older news, including cost-cutting measures and a halted asthma study, were overshadowed by the immediate positive developments.